MEDIKURA Revenue and Competitors
Estimated Revenue & Valuation
- MEDIKURA's estimated annual revenue is currently $2.8M per year.
- MEDIKURA's estimated revenue per employee is $98,000
Employee Data
- MEDIKURA has 29 Employees.
MEDIKURA's People
Name | Title | Email/Phone |
---|
MEDIKURA Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $12.6M | 90 | -36% | $14.1M | N/A |
#2 | $83.2M | 468 | -3% | $251M | N/A |
#3 | $14M | 100 | 1% | N/A | N/A |
#4 | $14.6M | 0 | N/A | $12.5M | N/A |
#5 | $30.3M | 197 | -6% | N/A | N/A |
#6 | $0.1M | 6 | -25% | $2.6M | N/A |
#7 | $45.1M | 293 | 2% | N/A | N/A |
#8 | $4.8M | 43 | -7% | N/A | N/A |
#9 | $399.3M | 2037 | 40% | N/A | N/A |
#10 | $44M | 286 | 4% | N/A | N/A |
What Is MEDIKURA?
MEDIKURA | The Future of Drug Safety: Digital Communication Infrastructure for Direct Exchange of Drug Side Effects & Innovative Software Solutions for Pharmaceutical/Biotech Companies & Healthcare Providers We are a dynamic young eHealth company and develop intelligent software applications, analysis tools and individual add-on services for pharmacovigilance. This enables the efficient recording, processing and evaluation of every incoming adverse drug reaction report, as well as the fast and secure initiation of necessary follow-up measures. * Gain valuable time through automated processes and seamless data integration. * Create trust through direct and secure exchange with patients and medical professionals. * Use valid real-world data for real-time drug monitoring and sound assessments of drug efficacy profiles. Join us in shaping the future of drug safety and learn more at www.medikura.com
keywords:N/AN/A
Total Funding
29
Number of Employees
$2.8M
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $7.3M | 29 | 7% | N/A |
#2 | $2.9M | 29 | 7% | N/A |
#3 | N/A | 29 | 142% | N/A |
#4 | $6.7M | 29 | 4% | N/A |
#5 | $2.9M | 29 | 7% | N/A |